DTC Implications: FDA Calls Foul on Magic Johnson Promotional DVD
This article was originally published in RPM Report
Executive Summary
FDA's criticisms of promotional DVD for Abbott's Kaletra highlight pitfalls of celebrity testimonials. FDA says too much of the session with the basketball star focuses on benefits from the drug; risk information is just an afterthought. The interview with the net star also demonstrates FDA concept of inaccurate "net impression." The DVD creates implied claim that drug works for five years - without supporting data.
You may also be interested in...
DTC Public Health Slant: A Winning Formula With FDA Commissioner Hamburg
FDA Commissioner Margaret Hamburg is not taking the easy way out when she discusses DTC, even in front of Congressional critics of the practice. She does not treat DTC as primarily a regulatory problem for the agency; instead she likes to focus on the public health potential of DTC.
DTC User Fees Shot Down; Advertisers Face More Perilous Future
The good news for advertisers: FDA will have more resources for pre-review of ads in 2008, funded by the taxpayers. The bad news: what happens in 2009?
Off-Label Sales in Jeopardy: Rx Industry Fights for Clarity
Off-label use of prescription drugs is worth billions of dollars to manufacturers, but no one likes to talk about it. Defensiveness is understandable, with scores of companies under investigations for allegedly promoting those uses illegally. The truth is that no one is very happy about the current state of off-label medication use, but calls for change are contradictory and tough to resolve.